Sponsor

Taiho Oncology, Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Taiho Oncology, Inc. appears in 25 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials25
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

25 shown
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.NCT05967689 · lead sponsor · 2023-07-31
RECRUITING
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionNCT07128199 · lead sponsor · 2025-12-22
ACTIVE_NOT_RECRUITING
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.NCT06506955 · lead sponsor · 2024-10-01
ACTIVE_NOT_RECRUITING
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)NCT05973773 · lead sponsor · 2023-12-18
ACTIVE_NOT_RECRUITING
A Study of TAS3351 in NSCLC Patients With EGFRmtNCT05765734 · lead sponsor · 2023-05-25
TERMINATED
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerNCT04965818 · lead sponsor · 2021-09-20
TERMINATED
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor CancerNCT04982926 · lead sponsor · 2021-09-16
TERMINATED
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor CancerNCT04586270 · lead sponsor · 2020-10-15
TERMINATED
A Study of TAS-120 in Patients With Metastatic Breast CancerNCT04024436 · lead sponsor · 2020-01-28
TERMINATED
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1NCT02855125 · lead sponsor · 2016-08-29
COMPLETED
Study of TAS3681 in Metastatic Castration Resistant Prostate CancerNCT02566772 · lead sponsor · 2016-03-01
COMPLETED
A Study of TAS-120 in Patients With Advanced Solid TumorsNCT02052778 · lead sponsor · 2014-07-21
COMPLETED
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPINCT01874522 · lead sponsor · 2013-07-01
COMPLETED
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based ChemotherapyNCT01904253 · lead sponsor · 2013-07-01
TERMINATED
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid TumorsNCT01867879 · lead sponsor · 2013-06-01
COMPLETED
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD AloneNCT01867866 · lead sponsor · 2013-05-01
COMPLETED
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung CancerNCT00652561 · lead sponsor · 2005-02-01
COMPLETED
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung CancerNCT00651833 · lead sponsor · 2005-02-01
COMPLETED
An EAP Treatment Protocol of ZipalertinibNCT07601399 · lead sponsor
AVAILABLE
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerNCT07710885 · collaborator · 2026-06-24
RECRUITING
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerNCT07229339 · collaborator · 2027-06-01
NOT_YET_RECRUITING
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLCNCT07802834 · collaborator · 2026-11-01
NOT_YET_RECRUITING
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerNCT04036682 · collaborator · 2019-10-31
ACTIVE_NOT_RECRUITING
TAS-102 in Extrapulmonary Neuroendocrine CarcinomaNCT04042714 · collaborator · 2019-08-15
TERMINATED
TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)NCT02920476 · collaborator · 2017-07-19
COMPLETED

Drugs studied in this sponsor's trials

9 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Taiho Oncology, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
futibatinib4
carboplatin1
cisplatin1
durvalumab1
gemcitabine1
pembrolizumab1
pemetrexed1
placebo1
futibatinib RxCUI 2628190 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 4 trials carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial durvalumab RxCUI 1919503 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial pembrolizumab RxCUI 1547545 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial pemetrexed RxCUI 68446 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial trifluridine RxCUI 10803 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor19
collaborator6
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.